UARK 2009-32 Compassionate Use Study of Carfilzomib (2009-32)
Compassionate Use Study of Carfilzomib for Patients With Relapsing or Resistant Multiple Myeloma
Sponsor: Onyx Therapeutics, Inc.
This observational or N/A phase trial investigates Multiple Myeloma and is currently ongoing. Onyx Therapeutics, Inc. leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Jan 2021 — Jul 2024 [monthly]
No Longer Available
-
Jun 2018 — Jan 2021 [monthly]
No Longer Available
-
Apr 2018 — Jun 2018 [monthly]
No Longer Available
Phase: NA → None
▶ Show 2 earlier versions
-
Feb 2017 — Apr 2018 [monthly]
No Longer Available NA
-
Jan 2017 — Feb 2017 [monthly]
No Longer Available NA
First recorded
Nov 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Onyx Therapeutics, Inc.
- University of Arkansas
For direct contact, visit the study record on ClinicalTrials.gov .